Jamie Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jamie Feng has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Drilon
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
8 shared publications - Julia Rotow
Dana-Farber Cancer Institute 4 Lowe Center for Thoracic Oncology Boston, Massachusetts
8 shared publications - Natasha B. Leighl
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
6 shared publications - Aaron Scott Mansfield
Mayo Clinic
5 shared publications - Alissa J. Cooper
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5 shared publications - Andrew Do
Department of Medicine, Mass General Brigham Cancer Institute, Boston, MA
5 shared publications
Latest Publications
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Second- and Third-Line Outcomes after Selective RET Inhibitor Failure in RET Fusion-Positive Metastatic Lung Cancer: A Real-World Analysis from the RET-MAP Registry
Purpose: Selective RET inhibitors (SRI) are the first-line standard for RET fusion–positive non–small cell lung cancer, but no treatment is established after progression. Real-world outcomes are needed to inform trial design and contextualize single-arm studies in this rare population. Experimental Design: Using the international RET-MAP registry (52 centers), we evaluated second-line platinum–pemetrexed (Pt-Pem) with or without immunotherapy (IO) after first-line SRI progression and characterized third-line treatments after exposure to both regimens in any order. Results: Among 207 patients treated with first-line SRI, 81 (39%) discontinued because of progression; 65 (80%) received subsequent therapy, most commonly Pt-Pem with or without IO (n = 35, 54%). At 53 months’ median follow-up, the real-world objective response rate was 41% (12/29), median real-world progression-free survival (rwPFS) was 6.1 months [95% confidence interval (CI), 4.8–11.4], and median overall survival (OS) was 13.7 months (95% CI, 8.7–26.5). Outcomes were similar with chemotherapy alone (n = 12) versus chemoimmunotherapy (n = 23) for rwPFS [5.9 vs. 6.8 months; hazard ratio (HR), 1.05; P = 0.903] and OS (18.5 vs. 13.7 months; HR, 0.83; P = 0.674). Three patients had rwPFS beyond 24 months with chemoimmunotherapy, all after short first-line SRI exposure. Among 32 patients receiving third-line therapy, taxane with or without antiangiogenic therapy was the most common (n = 11), with no responses and a median rwPFS of 1.5 months (95% CI, 0.8–NR). Conclusions: Second-line Pt-Pem with or without IO achieved a median rwPFS of 6.1 months. Third-line outcomes were poor, highlighting the need for new treatment strategies.
- 12 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Second- and Third-Line Outcomes after Selective RET Inhibitor Failure in RET Fusion-Positive Metastatic Lung Cancer: A Real-World Analysis from the RET-MAP Registry
Purpose: Selective RET inhibitors (SRI) are the first-line standard for RET fusion–positive non–small cell lung cancer, but no treatment is established after progression. Real-world outcomes are needed to inform trial design and contextualize single-arm studies in this rare population. Experimental Design: Using the international RET-MAP registry (52 centers), we evaluated second-line platinum–pemetrexed (Pt-Pem) with or without immunotherapy (IO) after first-line SRI progression and characterized third-line treatments after exposure to both regimens in any order. Results: Among 207 patients treated with first-line SRI, 81 (39%) discontinued because of progression; 65 (80%) received subsequent therapy, most commonly Pt-Pem with or without IO (n = 35, 54%). At 53 months’ median follow-up, the real-world objective response rate was 41% (12/29), median real-world progression-free survival (rwPFS) was 6.1 months [95% confidence interval (CI), 4.8–11.4], and median overall survival (OS) was 13.7 months (95% CI, 8.7–26.5). Outcomes were similar with chemotherapy alone (n = 12) versus chemoimmunotherapy (n = 23) for rwPFS [5.9 vs. 6.8 months; hazard ratio (HR), 1.05; P = 0.903] and OS (18.5 vs. 13.7 months; HR, 0.83; P = 0.674). Three patients had rwPFS beyond 24 months with chemoimmunotherapy, all after short first-line SRI exposure. Among 32 patients receiving third-line therapy, taxane with or without antiangiogenic therapy was the most common (n = 11), with no responses and a median rwPFS of 1.5 months (95% CI, 0.8–NR). Conclusions: Second-line Pt-Pem with or without IO achieved a median rwPFS of 6.1 months. Third-line outcomes were poor, highlighting the need for new treatment strategies.
- Open Access
- 20 July 2026
- Published by Elsevier in Lung Cancer
- Vol. 219, 109535
CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer
- 20 July 2026
- Published by Elsevier in Lung Cancer
- Vol. 219, 109535
Open AccessCT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer
- Open Access
- 2 July 2026
- Published by Wiley in Histopathology
- Vol. 89 (5) , 779-785
TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma
Introduction: TROP2 antibody‐drug conjugates have shown promising anti‐tumour activity, but neither the activity of these agents nor TROP2 expression has been well studied in pulmonary large cell neuroendocrine carcinoma (LCNEC), a rare and aggressive cancer type. We aimed to (i) determine the prevalence of TROP2 immunoreactivity in LCNEC; (ii) assess whether TROP2 immunoreactivity in LCNEC is related to RB1 loss on IHC or to the presence of NSCLC or SCLC components and (iii) determine whether TROP2 immunoreactivity in LCNEC has prognostic significance. Methods: TROP2 immunohistochemistry was performed on 58 pure LCNECs and 25 areas of LCNEC that were combined with other carcinomas, in tissue microarray format. TROP2 was scored for the percent of tumour cells staining, and with evaluation of cytoplasmic versus membranous staining, approximating a previously published predictive scoring method. Results: TROP2 staining in ≥1% and ≥50% of LCNEC cells was present in 60% and 26% of pure LCNEC tumours, respectively. Cytoplasmic‐type staining, previously implicated in greater antibody‐drug conjugate response, was present in 48% of pure LCNEC cases. Positive TROP2 staining was less frequent in pure LCNEC than in the LCNEC component of tumours that also contained a NSCLC component (≥1%: P = 0.0087; ≥50%: P = 0.011), and ≥50% TROP2 staining in pure LCNEC was associated with retained RB1 staining on immunohistochemistry ( P = 0.032). TROP2 staining was not associated with recurrence‐free survival or disease‐specific survival outcomes. Conclusion: Frequently positive TROP2 IHC suggests that TROP2 antibody‐drug conjugates may be potential treatments for LCNEC.
- 2 July 2026
- Published by Wiley in Histopathology
- Vol. 89 (5) , 779-785
Open AccessTROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma
Introduction: TROP2 antibody‐drug conjugates have shown promising anti‐tumour activity, but neither the activity of these agents nor TROP2 expression has been well studied in pulmonary large cell neuroendocrine carcinoma (LCNEC), a rare and aggressive cancer type. We aimed to (i) determine the prevalence of TROP2 immunoreactivity in LCNEC; (ii) assess whether TROP2 immunoreactivity in LCNEC is related to RB1 loss on IHC or to the presence of NSCLC or SCLC components and (iii) determine whether TROP2 immunoreactivity in LCNEC has prognostic significance. Methods: TROP2 immunohistochemistry was performed on 58 pure LCNECs and 25 areas of LCNEC that were combined with other carcinomas, in tissue microarray format. TROP2 was scored for the percent of tumour cells staining, and with evaluation of cytoplasmic versus membranous staining, approximating a previously published predictive scoring method. Results: TROP2 staining in ≥1% and ≥50% of LCNEC cells was present in 60% and 26% of pure LCNEC tumours, respectively. Cytoplasmic‐type staining, previously implicated in greater antibody‐drug conjugate response, was present in 48% of pure LCNEC cases. Positive TROP2 staining was less frequent in pure LCNEC than in the LCNEC component of tumours that also contained a NSCLC component (≥1%: P = 0.0087; ≥50%: P = 0.011), and ≥50% TROP2 staining in pure LCNEC was associated with retained RB1 staining on immunohistochemistry ( P = 0.032). TROP2 staining was not associated with recurrence‐free survival or disease‐specific survival outcomes. Conclusion: Frequently positive TROP2 IHC suggests that TROP2 antibody‐drug conjugates may be potential treatments for LCNEC.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
Supplementary Tables and Figures.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
Supplementary Tables and Figures.
- 27 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
Purpose: In RET-rearranged non–small cell lung cancer (NSCLC), treatment options after first-generation selective RET inhibitors (SRI) are limited, and the value of SRI retreatment remains unclear. This study evaluates outcomes of SRI retreatment. Experimental Design: This multicenter retrospective study included patients with advanced RET-rearranged NSCLC who received ≥2 SRI-based therapy lines. Of 411 SRI-treated patients, 41 (10%) underwent SRI retreatment. Outcomes included objective response rate (ORR), progression-free survival (PFS), 6-month PFS, time to treatment failure, adverse events (AE). Results: Among 41 patients, 14 (34%) discontinued the initial SRI because of toxicity and 27 (66%) because of progression. After discontinuation for toxicity, all switched to an alternate SRI, achieving an ORR of 67%, median PFS of 9.9 months, and 6-month PFS of 80.3%. AEs reoccurred in nine patients (64%), with grade ≥3 AEs in 3 (21%) who switched at full dose. Among patients who discontinued because of progression, SRI monotherapy (n = 13) achieved an ORR of 23%, median PFS of 7 months, and 6-month PFS of 61.5%. Benefit was observed in patients with brain-only or oligoprogressive disease or dose reduction on first SRI. Combination therapy (n = 14; targeted agents, n = 11; chemotherapy, n = 3) achieved an ORR of 39%, median PFS of 4 months, and 6-month PFS of 27.3%. Conclusions: Same-class SRI switch after toxicity is feasible and clinically active but warrants cautious, dose-adjusted switching to mitigate toxicities. The efficacy of SRI rechallenge after progression seems limited overall. However, selected patients, such as those with brain-only or oligoprogressive disease, may derive benefit.
- 27 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
Retreatment with First-Generation Selective RET Inhibitors in RET -Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry
Purpose: In RET-rearranged non–small cell lung cancer (NSCLC), treatment options after first-generation selective RET inhibitors (SRI) are limited, and the value of SRI retreatment remains unclear. This study evaluates outcomes of SRI retreatment. Experimental Design: This multicenter retrospective study included patients with advanced RET-rearranged NSCLC who received ≥2 SRI-based therapy lines. Of 411 SRI-treated patients, 41 (10%) underwent SRI retreatment. Outcomes included objective response rate (ORR), progression-free survival (PFS), 6-month PFS, time to treatment failure, adverse events (AE). Results: Among 41 patients, 14 (34%) discontinued the initial SRI because of toxicity and 27 (66%) because of progression. After discontinuation for toxicity, all switched to an alternate SRI, achieving an ORR of 67%, median PFS of 9.9 months, and 6-month PFS of 80.3%. AEs reoccurred in nine patients (64%), with grade ≥3 AEs in 3 (21%) who switched at full dose. Among patients who discontinued because of progression, SRI monotherapy (n = 13) achieved an ORR of 23%, median PFS of 7 months, and 6-month PFS of 61.5%. Benefit was observed in patients with brain-only or oligoprogressive disease or dose reduction on first SRI. Combination therapy (n = 14; targeted agents, n = 11; chemotherapy, n = 3) achieved an ORR of 39%, median PFS of 4 months, and 6-month PFS of 27.3%. Conclusions: Same-class SRI switch after toxicity is feasible and clinically active but warrants cautious, dose-adjusted switching to mitigate toxicities. The efficacy of SRI rechallenge after progression seems limited overall. However, selected patients, such as those with brain-only or oligoprogressive disease, may derive benefit.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Pre- and post-SRI next-generation sequencing results provided
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Pre- and post-SRI next-generation sequencing results provided
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Acquired genomic alterations identified by post-progression biopsies after selective RET inhibitors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Acquired genomic alterations identified by post-progression biopsies after selective RET inhibitors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Clinical and Molecular Characteristics of Cases of Acquired MET Amplification Identified by Next-Generation Sequencing after Selective RET Inhibitors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Clinical and Molecular Characteristics of Cases of Acquired MET Amplification Identified by Next-Generation Sequencing after Selective RET Inhibitors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Clinical and Molecular Characteristics of Cases of RET Gain Identified by Next-Generation Sequencing after Selective RET Inhibitors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Clinical and Molecular Characteristics of Cases of RET Gain Identified by Next-Generation Sequencing after Selective RET Inhibitors
- 15 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1157-1168
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.
- 15 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1157-1168
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.